Telitacicept in the Treatment of Lupus Nephritis: A Prospective Real-world Study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091818

Enrollment

Unknown

Registered

2024-11-04

Start date

2023-01-13

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus nephritis

Interventions

Telitacicept :None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with long-term follow-up in the lupus nephritis clinic of our center. 2.Males or females aged at least 18 years. 3.Signing informed consent. 4.Have a clinical diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR) criteria(1997). 5.Renal biopsy proved lupus nephritis or patients with long-term renal involvement indicators: proteinuria (24-hour urinary protein > 0.5g ) and/or hematuria (microscopic red blood cells > 3 / HP ), and/or non-infectious purulent urine (microscopic white blood cells > 5 / HP ).

Exclusion criteria

Exclusion criteria: 1.Refused to sign informed consent. 2.It is known to be allergic or intolerant to the drug. 3.Clinical active infection: including but not limited to: herpes zoster, tuberculosis, etc. 4.Women during pregnancy and lactation, or recent pregnancy plans. 5.Involved in clinical research of other drugs.

Design outcomes

Primary

Measure	Time frame
Systemic lupus erythematosus disease activity improves SRI-4;Complete renal remission;Partial renal remission;Safety;	—

Countries

China

Contacts

Public ContactTan Ying

Peking University First Hospital

tanying@bjmu.edu.cn+86 136 9305 0537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026